Published: 13 September 2019
Author(s): Silvia Scabini, Tommaso Lupia, Roberto Angilletta, Francesco Giuseppe De Rosa, Silvia Corcione
Section: Letter to the Editor
Real-world data on efficacy and safety of isavuconazole (ISV) are mostly based on cohorts of patients with hematological malignancies, stem cells or solid organ transplants (i.e., HSCT or SOT) [1,2].
